Lakefront Biotherapeutics NV (LKFT) stock

LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 26, 2026Score 7/30

$33.98+0.05 (+0.15%)

Close on Nov 13, 2026Market cap $2.24BP/E 6.3Yield –

Lakefront Biotherapeutics statistics

75 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: –
Last ex-dividend date: No dividends
Fundamentals through: Dec 31, 2025
Share price as of: –

Valuation ratiosIndustry

Market Cap: €2.01B; €768.08M
Enterprise Value: €1.92B; €535.62M
PE Ratio: 6.26; –
PS Ratio: 1.80; 7.25

Enterprise valuationIndustry

EV / Sales: 1.73; 4.04
EV / EBITDA: 6.51; 6.51
EV / EBIT: 6.51; –

Share statisticsIndustry

Shares Outstanding: 66M; 100M
Shares Change (YoY): 0.00%; 5.61%
Float: 36M; 79M
Shares Held by Insiders: 45.1%; 9.05%
Shares Held by Institutions: 48.6%; 20.8%

Short sellingIndustry

Short Interest: 1M; –
Short Interest Change: -8.25%; -2.55%
Days to Cover: 5.96; 3.54

Stock price statisticsIndustry

Price Change (1 Week): 1.58%; 0.08%
Price Change (1 Month): 13.5%; -2.76%
Price Change (3 Months): 23.5%; -21.7%
Price Change (6 Months): 25.6%; -11.3%
Price Change (YTD): 3.91%; -15.5%
Price Change (1 Year): 5.17%; -17.6%
Price Change (3 Years): -9.05%; -8.10%
Price Change (5 Years): -35.7%; -54.7%
Price Change (10 Years): -43.1%; -44.0%
Average Volume (10 Days): 312,560; –
Average Volume (20 Days): 266,857; –
Average Volume (90 Days): 268,262; –
Relative Volume: 1.08; 0.63
Relative Strength Index (14): 71.4; 48.4
Volatility (1 Year): 27.5%; 65.2%
Beta (5 Years): 0.57; 0.86

MarginsIndustry

Gross Margin: 97.3%; 42.5%
Operating Margin: 26.5%; -33.2%
Pretax Margin: 27.1%; -36.6%
Profit Margin: 28.8%; 5.34%
EBITDA Margin: 26.5%; -28.6%
FCF Margin: -24.4%; -24.4%

Returns on capitalIndustry

Return on Assets (ROA): 8.51%; -1.57%
Return on Capital Employed (ROCE): 9.07%; -23.8%

Financial positionIndustry

Current Ratio: 20.15; 3.49
Quick Ratio: 0.71; 1.51
Interest Coverage: 285.34; -0.71

GrowthIndustry

Revenue Growth (YoY): 303.5%; -1.08%
Net Income Growth (YoY): 333.1%; –
EPS Growth (YoY): 334.8%; 67.4%
Revenue Growth (3Y CAGR): 66.4%; 1.61%
Revenue Growth (5Y CAGR): 18.4%; 14.0%

EfficiencyIndustry

Asset Turnover: 0.29; 0.31
Inventory Turnover: 0.81; 1.36
Revenue Per Employee: €2.46M; €855.98K
Profits Per Employee: €709.92K; -€43.26K
Employee Count: 452; 304
WACC: 7.94%; 9.49%

Income statement (TTM)Industry

Revenue: €1.11B; €465.66M
Gross Profit: €1.08B; €1.08B
Operating Income: €295.04M; -€54.01M
Pretax Income: €300.87M; -€47.40M
Net Income: €320.88M; €157.18M
EBITDA: €295.04M; -€42.85M
EPS (Diluted): 4.87 EUR; -0.55 EUR

Balance sheetIndustry

Cash & Short-Term Investments: €87.87M; €199.29M
Net Cash (Debt): €87.87M; €111.50M
Net Cash Per Share: 1.33 EUR; 1.53 EUR
Working Capital: €2.93B; €119.55M

Cash flow (TTM)Industry

Operating Cash Flow: -€257.46M; -€42.16M
Capital Expenditures: -€13.70M; -€2.34M
Free Cash Flow: -€271.16M; -€52.90M
FCF Per Share: -4.11 EUR; -0.48 EUR

Dividends and yieldsIndustry

Earnings Yield: 16.0%; -1.80%
FCF Yield: -13.5%; -13.3%

Taxes and interestIndustry

Interest Expense: €1.03M; €55.20M
Income Tax: -€18.62M; €80.00K
Effective Tax Rate: -6.19%; –

Scores and fair valueIndustry

Altman Z-Score: 8.79; 1.23
Piotroski F-Score: 7; 5

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

Period	LKFT	S&P 500	Difference	LKFT per year	S&P 500 per year
1 month	+17.0%	-3.0%	+20.0 pts
3 months	+21.2%	-2.8%	+24.0 pts
Year to date	+3.9%	+11.5%	−7.6 pts
1 year	+7.9%	+13.5%	−5.6 pts
3 years	-6.6%	+77.7%	−84.3 pts	-2.2%	+21.1%
5 years	-35.7%	+72.6%	−108.3 pts	-8.4%	+11.5%
10 years	-42.9%	+308.2%	−351.1 pts	-5.5%	+15.1%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

1M LKFT shares were sold short on Oct 30, 2026, down 8.2% from the previous report. At recent volumes it would take 6.0 days to buy them back. Over the last 20 sessions, 57.1% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	1,299,291	-8.2%	217,859	6.0
Oct 15, 2026	1,416,118	-57.3%	297,058	4.8
Sep 30, 2026	3,317,951	-2.8%	349,965	9.5
Sep 15, 2026	3,413,512	+3.6%	276,452	12.3
Aug 31, 2026	3,295,220	+10.8%	235,313	14.0
Aug 14, 2026	2,972,977	+17.9%	292,338	10.2
Jul 31, 2026	2,521,939	+8.6%	179,544	14.1
Jul 15, 2026	2,323,166	+3.8%	143,810	16.1
Jun 30, 2026	2,238,240	+2.5%	141,603	15.8
Jun 15, 2026	2,183,405	+16.6%	225,785	9.7
May 29, 2026	1,871,825	+16.8%	140,516	13.3
May 15, 2026	1,602,902	+11.6%	170,713	9.4

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

Where these numbers come from

Parsed from the XBRL in Lakefront Biotherapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is LKFT.

Compare: LKFT vs KNSA · LKFT vs INSM · LKFT vs TGTX · LKFT vs LEGN · LKFT vs PTCT

Revenue growth303.5% · median 59.5%

Gross margin97.3% · median 83.6%

Operating margin26.5% · median 12.8%

Net margin28.9% · median 1.2%

Company	Revenue	Growth
INSM	$1.52B	+240.0%
LEGN	$1.27B	+59.5%
PTCT	$1.16B	-35.1%
LKFT	€1.11B	+303.5%
KNSA	$945.96M	+58.2%
TGTX	$897.76M	+68.8%

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Employees: 452
Auditor: BDO Bedrijfsrevisoren BV
SEC CIK: 1421876

Advertisement
300 × 250

See a number that looks wrong?